2005-2009 Publications

2005

  1. Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, Barlogie B, Berenson JR, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, Anderson KC, .Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood, 2005 Dec 1;106(12);3777-84. PMID: 16099887
  2. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc, 2005 Dec;136(12);1658-68. PMID: 16383047
  3. Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer, 2005 Nov 15;104(10);2141-8. PMID: 16206291
  4. Mahfouz T, Miceli MH, Saghafifar F, Stroud S, Jones-Jackson L, Walker R, Grazziutti ML, Purnell G, Fassas A, Tricot G, Barlogie B, Anaissie E. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. J Clin Oncol, 2005 Nov 1;23(31);7857-63. PMID: 16204017
  5. Batchu RB, Moreno AM, Szmania SM, Bennett G, Spagnoli GC, Ponnazhagan S, Barlogie B, Tricot G, van Rhee F.Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. Cancer Res, 2005 Nov 1;65(21);10041-9. PMID: 16267030
  6. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Hideshima T, Xiao H, Esseltine D, Schenkein D, Anderson KC, . Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood, 2005 Nov 1;106(9);2977-81. PMID: 16020506
  7. Yaccoby S. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clin Cancer Res, 2005 Nov 1;11(21);7599-606.PMID: 16278377
  8. Suzuki A, Iida S, Kato-Uranishi M, Tajima E, Zhan F, Hanamura I, Huang Y, Ogura T, Takahashi S, Ueda R, Barlogie B, Shaughnessy J Jr, Esumi H. ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma. Oncogene, 2005 Oct 20;24(46);6936-44. PMID: 16044163
  9. Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P, Tricot G. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol, 2005 Oct;131(1);71-3. PMID: 16173965
  10. Qiang YW, Walsh K, Yao L, Kedei N, Blumberg PM, Rubin JS, Shaughnessy J Jr, Rudikoff S. Wnts induce migration and invasion of myeloma plasma cells. Blood, 2005 Sep 1;106(5);1786-93. PMID: 15886323
  11. Talamo G, Angtuaco E, Walker RC, Dong L, Miceli MH, Zangari M, Tricot G, Barlogie B, Anaissie E. Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy. J Clin Oncol, 2005 Aug 1;23(22);5217-23. PMID: 15955903
  12. Neelapu SS, Munshi NC, Jagannath S, Watson TM, Pennington R, Reynolds C, Barlogie B, Kwak LW. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant, 2005 Aug;36(4);315-23. PMID: 15968284
  13. Fassas AB, Miceli MH, Grazzlutti M, Dong L, Barlogie B, Anaissie E. Serial measurement of serum C-reactive protein levels can identify patients at risk for severe complications following autologous stem cell transplantation. Leuk Lymphoma, 2005 Aug;46(8);1159-61. PMID: 16085556
  14. Barlogie B. The role of transplant in multiple myeloma. Clin Adv Hematol Oncol, 2005 Aug;3(8);604-6. PMID: 16167043
  15. Kamble R, Wilson CS, Fassas A, Desikan R, Siegel DS, Tricot G, Anderson P, Sawyer J, Anaissie E, Barlogie B.Malignant pleural effusion of multiple myeloma: prognostic factors and outcome. Leuk Lymphoma, 2005 Aug;46(8);1137-42. PMID: 16085553
  16. Hong H, Dragan Y, Epstein J, Teitel C, Chen B, Xie Q, Fang H, Shi L, Perkins R, Tong W. Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS). BMC Bioinformatics, 2005 Jul 15;6 Suppl 2S5. PMID: 16026602
  17. Dignani MC, Rex JH, Chan KW, Dow G, deMagalhaes-Silverman M, Maddox A, Walsh T, Anaissie E.Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia. Cancer, 2005 Jul 1;104(1);199-204. PMID: 15929126
  18. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood, 2005 Jul 1;106(1);296-303. PMID: 15755896
  19. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Harousseau JL, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol, 2005 May 20;23(15);3412-20. PMID: 15809451
  20. van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, Batchu RB, Moreno A, Spagnoli G, Shaughnessy J, Tricot G. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood, 2005 May 15;105(10);3939-44. PMID: 15671442
  21. Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, Orlowski RZ, Richardson PG, Anderson J, Nix D, Esseltine DL, Anderson KC, . Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer, 2005 Mar 15;103(6);1195-200. PMID: 15690325
  22. Yang Y, Macleod V, Bendre M, Huang Y, Theus AM, Miao HQ, Kussie P, Yaccoby S, Epstein J, Suva LJ, Kelly T, Sanderson RD. Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood, 2005 Feb 1;105(3);1303-9. PMID: 15471949
  23. Fassas A, Shaughnessy J, Barlogie B. Cure of myeloma: hype or reality? Bone Marrow Transplant, 2005 Feb;35(3);215-24. PMID: 15543196
  24. Fassas A, Barlogie B, Feusner J, Kay NE, Wingard JR. Highlights from the 46 th annual meeting of the American Society of Hematology. Clin Adv Hematol Oncol, 2005 Feb;3(2);111-6. PMID: 16166978
  25. Sawyer JR, Tricot G, Lukacs JL, Binz RL, Tian E, Barlogie B, Shaughnessy J Jr. Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q. Genes Chromosomes Cancer, 2005 Jan;42(1);95-106. PMID: 15472896
  26. Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology, 2005;10 Suppl 1117-26. PMID: 16188652
  27. Epstein J, Yaccoby S. The SCID-hu myeloma model. Methods Mol Med, 2005;113183-90. PMID: 15968103
  28. Szmania S, Yi Q, Cottler-Fox M, Rosen NA, Freeman J, Kordsmeier BJ, Moreno A, Shi J, Barlogie B, Tricot G, van Rhee F. Clinical-grade myeloma Ag pre-loaded DC vaccines retain potency after cryopreservation.Cytotherapy, 2005;7(4);374-84. PMID: 16162460
  29. Shaughnessy J Jr, Zhan F, Barlogie B, Stewart AK. Gene expression profiling and multiple myeloma. Best Pract Res Clin Haematol, 2005;18(4);537-52. PMID: 16026736

2006

  1. Anaissie EJ, Segal BH, Graybill JR, Arndt C, Perfect JR, Kleinberg M, Pappas P, Benjamin D, Rubin R, Aberg JA, Adderson EE, Adler-Shohet FC, Akan H, Akova M, Almyroudis NG, Alexander BD, Andes D, Arrieta A, Baddley JW, Barron MA, Belzberg H, Boucher HW, Boyce TG, Casadevall A, Chandrasekar PH, Cleary JD, Cordonnier C, Cornely OA, Cuenca-Estrella M, Daly JS, Daoura N, Denning DW, dePauw B, de Repentigny L, Dignani MC, Dismukes WE, Donnelly JP, Donowitz GR, Dupont B, Drusano G, Ellis M, Espinel-Ingroff A, Fishman JA, Fleming R, Forrest G, Ghannoum M, Goldman M, Grazziutti M, Greene JN, Greenberg RN, Gubbins PO, Hadley S, Herbrecht R, Hiemenz JW, Hope W, Hospenthal DR, Husain S, Ito JI, Jacobson RM, Johnson M, Keating MR, Kett DH, Knapp K, Kontoyiannis DP, Krcmery VC, Larsen R, Laverdiere M, Ljungman P, Lortholary O, Maertens J, Marriott D, Mattiuzzi G, McGinnis MR, Morris M, Nucci M, Odds FC, Pankey GA, Patterson T, Pfaller M, Razonable RR, Reboli AC, Rinaldi MG, Roberts GD, Rodriguez Tudela JL, Rotstein C, Ruhnke M, Schuster M, Shoham S, Sia IG, Siebel N, Silviera F, Singh N, Sobel J, Solomkin JS, Sorrell TC, Steinbach WJ, Temesgen Z, Tortorano A, Vartivarian S, VerWeij P, Viscoli C, Viviani MA, Walker RC, Wheat JL, Wiley J, Williamson P, Wingard JR, Yu VL, Zaoutis T.Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. Clin Infect Dis, 2006 Oct 15;43(8);1031-9. PMID: 16983616
  2. Yang J, Qian J, Wezeman M, Wang S, Lin P, Wang M, Yaccoby S, Kwak LW, Barlogie B, Yi Q. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell, 2006 Oct;10(4);295-307. PMID: 17045207
  3. Grazziutti ML, Dong L, Miceli MH, Krishna SG, Kiwan E, Syed N, Fassas A, van Rhee F, Klaus H, Barlogie B, Anaissie EJ. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant, 2006 Oct;38(7);501-6. PMID: 16980998
  4. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J, Shaughnessy JD, Jagannath S, Bolejack V, Gurley J, Hoering A, Vesole D, Desikan R, Siegel D, Mehta J, Singhal S, Munshi NC, Dhodapkar M, Jenkins B, Attal M, Harousseau JL, Crowley J. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol, 2006 Oct;135(2);158-64. PMID: 16939489
  5. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD Jr. The molecular classification of multiple myeloma. Blood, 2006 Sep 15;108(6);2020-8.PMID: 16728703
  6. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, Hollmig K, Zangarri M, Pineda-Roman M, van Rhee F, Cavallo F, Burington B, Crowley J, Tricot G, Barlogie B, Shaughnessy JD Jr. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood, 2006 Sep 1;108(5);1724-32. PMID: 16705089
  7. Zangari M, Yaccoby S, Cavallo F, Esseltine D, Tricot G. Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma, 2006 Sep;7(2);109-14. PMID: 17026821
  8. Lazarevic V, Wahlin A, Hultdin M, Zhan F, Shaughnessy J. Chronic lymphocytic leukemia with osteolytic Richter’s syndrome mimicking myeloma bone disease shows no over-expression of DKK1. Leuk Lymphoma, 2006 Sep;47(9);1987-8. PMID: 17065022
  9. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV, . International uniform response criteria for multiple myeloma. Leukemia, 2006 Sep;20(9);1467-73. PMID: 16855634
  10. Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol, 2006 Aug;134(4);399-405. PMID: 16882132
  11. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol, 2006 Jul 1;24(19);3113-20. PMID: 16754936
  12. Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood, 2006 Jul 1;108(1);403; author reply 404. PMID: 16790586
  13. Hanamura I, Huang Y, Zhan F, Barlogie B, Shaughnessy J. Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations. Leukemia, 2006 Jul;20(7);1288-90. PMID: 16688228
  14. Talamo G, Cavallo F, Zangari M, Barlogie B, Lee CK, Pineda-Roman M, Kiwan E, Krishna S, Tricot G. Clinical and biological features of multiple myeloma involving the gastrointestinal system. Haematologica, 2006 Jul;91(7);964-7. PMID: 16818286
  15. Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL, Anderson KC, . Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.Haematologica, 2006 Jul;91(7);929-34. PMID: 16818280
  16. Shaughnessy JD Jr. Clinical use of genomics in multiple myeloma. Clin Adv Hematol Oncol, 2006 Jun;4(6);419-21. PMID: 16981662
  17. Stewart JP, Shaughnessy JD Jr. Role of osteoblast suppression in multiple myeloma. J Cell Biochem, 2006 May 1;98(1);1-13. PMID: 16440324
  18. Barlogie B, Zangari M, Bolejack V, Hollmig K, Anaissie E, van Rhee F, Pineda-Roman M, Mohiuddin A, Crowley J, Tricot G. Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma. Clin Lymphoma Myeloma, 2006 May;6(6);469-74. PMID: 16796777
  19. Miceli MH, Dong L, Grazziutti ML, Fassas A, Thertulien R, Van Rhee F, Barlogie B, Anaissie EJ. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant, 2006 May;37(9);857-64. PMID: 16532017
  20. Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, Fassas A, Hollmig K, Pineda-Roman M, Shaughnessy J, Epstein J, Crowley J. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood, 2006 Apr 1;107(7);2633-8. PMID: 16322468
  21. Ge Y, Zhan F, Barlogie B, Epstein J, Shaughnessy J Jr, Yaccoby S. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. Br J Haematol, 2006 Apr;133(1);83-92. PMID: 16512833
  22. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, Stephens O, Barlogie B, Anderson KC, Chin L, Shaughnessy JD Jr, Brennan C, Depinho RA. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell, 2006 Apr;9(4);313-25. PMID: 16616336
  23. Epstein J, Walker R. Myeloma and bone disease: “the dangerous tango”. Clin Adv Hematol Oncol, 2006 Apr;4(4);300-6. PMID: 16728940
  24. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, Rajkumar SV, Srkalovic G, Alsina M, Anderson KC. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial. Cancer, 2006 Mar 15;106(6);1316-9. PMID: 16470606
  25. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med, 2006 Mar 9;354(10);1021-30. PMID: 16525139
  26. Lee CK, Zangari M, Fassas A, Thertulien R, Talamo G, Badros A, Cottler-Fox M, van Rhee F, Barlogie B, Tricot G.Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation. Bone Marrow Transplant, 2006 Mar;37(5);511-5. PMID: 16435020
  27. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol, 2006 Feb 20;24(6);929-36. PMID: 16432076
  28. Takebe N, Cheng X, Fandy TE, Srivastava RK, Wu S, Shankar S, Bauer K, Shaughnessy J, Tricot G. IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells. Mol Cancer Ther, 2006 Feb;5(2);457-66. PMID: 16505121
  29. Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, Gaddy D, Ling W, Saha R, Barlogie B, Tricot G, Epstein J. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica, 2006 Feb;91(2);192-9. PMID: 16461303
  30. Grazziutti ML, Dong L, Miceli MH, Cottler-Fox M, Krishna SG, Fassas A, van Rhee F, Barlogie BM, Anaissie EJ.Recovery from neutropenia can be predicted by the immature reticulocyte fraction several days before neutrophil recovery in autologous stem cell transplant recipients. Bone Marrow Transplant, 2006 Feb;37(4);403-9. PMID: 16400338
  31. Toor AA, Ramdane BA, Joseph J, Thomas M, O’Hara C, Barlogie B, Walker P, Joseph L. Cardiac nonamyloidotic immunoglobulin deposition disease. Mod Pathol, 2006 Feb;19(2);233-7. PMID: 16341150
  32. Shaughnessy JD Jr, Barlogie B. Using genomics to identify high-risk myeloma after autologous stem cell transplantation. Biol Blood Marrow Transplant, 2006 Jan;12(1 Suppl 1);77-80. PMID: 16399589
  33. Bhattacharyya S, Epstein J, Suva LJ. Biomarkers that discriminate multiple myeloma patients with or without skeletal involvement detected using SELDI-TOF mass spectrometry and statistical and machine learning tools. Dis Markers, 2006;22(4);245-55. PMID: 17124346
  34. Dib A, Peterson TR, Raducha-Grace L, Zingone A, Zhan F, Hanamura I, Barlogie B, Shaughnessy J Jr, Kuehl WM.Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression. Cell Div, 2006;123. PMID: 17049078

2007

  1. Haessler J, Shaughnessy JD Jr, Zhan F, Crowley J, Epstein J, van Rhee F, Anaissie E, Pineda-Roman M, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Tricot G, Barlogie B. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res, 2007 Dec 1;13(23);7073-9. PMID: 18056185
  2. Barlogie B, Anaissie E, van Rhee F, Pineda-Roman M, Zangari M, Shaughnessy J, Epstein J, Crowley J. The Arkansas approach to therapy of patients with multiple myeloma. Best Pract Res Clin Haematol, 2007 Dec;20(4);761-81. PMID: 18070718
  3. Szmania S, Gnjatic S, Tricot G, Stone K, Zhan F, Moreno A, Thuro B, Melenhorst J, Barrett J, Shaughnessy J, Old LJ, Barlogie B, Brichard VG, van Rhee F. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. J Immunother, 2007 Nov-Dec;30(8);847-54. PMID: 18049337
  4. Zangari M, Barlogie B, Cavallo F, Bolejack V, Fink L, Tricot G. Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients. Blood Coagul Fibrinolysis, 2007 Oct;18(7);595-8. PMID: 17890944
  5. Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, Sasisekharan R, Naggi A, Torri G, Casu B, Vlodavsky I, Suva LJ, Epstein J, Yaccoby S, Shaughnessy JD Jr, Barlogie B, Sanderson RD. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood, 2007 Sep 15;110(6);2041-8. PMID: 17536013
  6. Prasad HK, Zhan F, Shaughnessy J. Smoldering multiple myeloma. N Engl J Med, 2007 Sep 6;357(10);1048; author reply 1049-50. PMID: 17804853
  7. Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, Wang M, Zhan F, Shaughnessy JD Jr, Epstein J, Kwak LW, Yi Q.Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma.Blood, 2007 Sep 1;110(5);1587-94. PMID: 17515399
  8. Li X, Pennisi A, Zhan F, Sawyer JR, Shaughnessy JD, Yaccoby S. Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines. Br J Haematol, 2007 Sep;138(6);802-11.PMID: 17760811
  9. Zangari M, Esseltine D, Cavallo F, Neuwirth R, Elice F, Burns MJ, Yaccoby S, Richardson P, Sonneveld P, Tricot G.Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. Am J Hematol, 2007 Sep;82(9);831-3. PMID: 17546639
  10. Woods G, Miceli MH, Grazziutti ML, Zhao W, Barlogie B, Anaissie E. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer, 2007 Aug 15;110(4);830-4. PMID: 17607669
  11. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, Shaughnessy JD Jr, Zangari M, Tricot G, Mohiuddin A, Alsayed Y, Woods G, Crowley J, Barlogie B. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.Blood, 2007 Aug 1;110(3);827-32. PMID: 17416735
  12. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD Jr, Kuehl WM, Staudt LM. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell, 2007 Aug;12(2);115-30. PMID: 17692804
  13. Miceli MH, Maertens J, Buvé K, Grazziutti M, Woods G, Rahman M, Barlogie B, Anaissie EJ. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications. Cancer, 2007 Jul 1;110(1);112-20. PMID: 17525971
  14. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J, Shaughnessy JD Jr. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol, 2007 Jul;138(2);176-85. PMID: 17593024
  15. van Rhee F, Crowley J, Barlogie B. Allografting or autografting for myeloma. N Engl J Med, 2007 Jun 21;356(25);2646-8; author reply 2646-8. PMID: 17582078
  16. Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM, Barlogie B, Shaughnessy JD Jr. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood, 2007 Jun 1;109(11);4995-5001. PMID: 17303695
  17. Shaughnessy JD Jr, Haessler J, van Rhee F, Anaissie E, Pineda-Roman M, Cottler-Fox M, Hollmig K, Zangari M, Mohiuddin A, Alsayed Y, Grazziutti M, Epstein J, Crowley J, Barlogie B. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. Br J Haematol, 2007 Jun;137(6);530-6. PMID: 17489983
  18. Colla S, Zhan F, Xiong W, Wu X, Xu H, Stephens O, Yaccoby S, Epstein J, Barlogie B, Shaughnessy JD Jr. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood, 2007 May 15;109(10);4470-7. PMID: 17255354
  19. Yang Y, Macleod V, Miao HQ, Theus A, Zhan F, Shaughnessy JD Jr, Sawyer J, Li JP, Zcharia E, Vlodavsky I, Sanderson RD. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem, 2007 May 4;282(18);13326-33. PMID: 17347152
  20. Talamo G, Cavallo F, Zangari M, Barlogie B, Lee CK, Pineda-Roman M, Kiwan E, Krishna S, Tricot G.Hyperammonemia and encephalopathy in patients with multiple myeloma. Am J Hematol, 2007 May;82(5);414-5. PMID: 17133420
  21. Claudio JO, Zhan F, Zhuang L, Khaja R, Zhu YX, Sivananthan K, Trudel S, Masih-Khan E, Fonseca R, Bergsagel PL, Scherer SW, Shaughnessy J, Stewart AK. Expression and mutation status of candidate kinases in multiple myeloma. Leukemia, 2007 May;21(5);1124-7. PMID: 17344920
  22. Spisek R, Kukreja A, Chen LC, Matthews P, Mazumder A, Vesole D, Jagannath S, Zebroski HA, Simpson AJ, Ritter G, Durie B, Crowley J, Shaughnessy JD Jr, Scanlan MJ, Gure AO, Barlogie B, Dhodapkar MV. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med, 2007 Apr 16;204(4);831-40. PMID: 17389240
  23. Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, Koenig E, Fergus A, Huang Y, Richardson P, Trepicchio WL, Broyl A, Sonneveld P, Shaughnessy JD Jr, Bergsagel PL, Schenkein D, Esseltine DL, Boral A, Anderson KC. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood, 2007 Apr 15;109(8);3177-88. PMID: 17185464
  24. Zhan FH, Barlogie B, John D S Jr. Gene expression profiling defines a high-risk entity of multiple myeloma.Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2007 Apr;32(2);191-203. PMID: 17478923
  25. Gokden N, Zangari M, Elici F, Barlogie B, Kumar J. Potential effect of zoledronate therapy in heavy proteinuria. Clin Nephrol, 2007 Apr;67(4);263-5. PMID: 17474565
  26. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr, Epstein J, van Hemert R, Erdem E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangari M, Pineda-Roman M, Mohiuddin A, Yaccoby S, Sawyer J, Angtuaco EJ. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol, 2007 Mar 20;25(9);1121-8. PMID: 17296972
  27. Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood, 2007 Mar 15;109(6);2276-84. PMID: 17105813
  28. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD Jr. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood, 2007 Mar 1;109(5);2106-11. PMID: 17068150
  29. Clarke BM, Boyette J, Vural E, Suen JY, Anaissie EJ, Stack BC Jr. Bisphosphonates and jaw osteonecrosis: the UAMS experience. Otolaryngol Head Neck Surg, 2007 Mar;136(3);396-400. PMID: 17321866
  30. Gokden N, Cetin N, Colakoglu N, Kumar J, Abul-Ezz S, Barlogie B, Liapis H, Walker PD. Morphologic manifestations of combined light-chain deposition disease and light-chain cast nephropathy. Ultrastruct Pathol, 2007 Mar-Apr;31(2);141-9. PMID: 17613994
  31. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Zangari M, Dhodapkar M, Shaughnessy JD Jr. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood, 2007 Feb 15;109(4);1692-700. PMID: 17023574
  32. Dib A, Barlogie B, Shaughnessy JD Jr, Kuehl WM. Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma. Blood, 2007 Feb 1;109(3);1337-8. PMID: 17244692
  33. Pineda-Roman M, Bolejack V, Arzoumanian V, Anaissie E, van Rhee F, Zangari M, Walker R, Hollmig K, Shaughnessy JD Jr, Epstein J, Krishna S, Crowley J, Barlogie B. Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol, 2007 Feb;136(3);393-9. PMID: 17156398
  34. Clines GA, Mohammad KS, Bao Y, Stephens OW, Suva LJ, Shaughnessy JD Jr, Fox JW, Chirgwin JM, Guise TA.Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol, 2007 Feb;21(2);486-98. PMID: 17068196
  35. Park ES, Shaughnessy JD Jr, Gupta S, Wang H, Lee JS, Woo HG, Zhan F, Owens JD Jr, Potter M, Janz S, Mushinski JF. Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia. BMC Genomics, 2007;8302. PMID: 17764

2008

  1. Anaissie EJ. Diagnosis and therapy of fungal infection in patients with leukemia–new drugs and immunotherapy. Best Pract Res Clin Haematol, 2008 Dec;21(4);683-90. PMID: 19041608
  2. Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, Moreno A, Dupont B, Hsu KC, Baxter-Lowe LA, Cottler-Fox M, Shaughnessy JD Jr, Barlogie B, van Rhee F. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol, 2008 Dec;143(5);641-53. PMID: 18950462
  3. Barlogie B, Epstein J, Shaughnessy JD Jr. Going with the flow, and beyond, in myeloma. Blood, 2008 Nov 15;112(10);3917-8. PMID: 18988869
  4. Xiong W, Wu X, Starnes S, Johnson SK, Haessler J, Wang S, Chen L, Barlogie B, Shaughnessy JD Jr, Zhan F. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood, 2008 Nov 15;112(10);4235-46. PMID: 18337559
  5. Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Esseltine DL, Anderson KC. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol, 2008 Nov;143(4);537-40. PMID: 18783399
  6. Tricot G, Barlogie B, Zangari M, van Rhee F, Hoering A, Szymonifka J, Cottler-Fox M. Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy.Haematologica, 2008 Nov;93(11);1739-42. PMID: 18728024
  7. Barlogie B, van Rhee F, Shaughnessy JD Jr, Epstein J, Yaccoby S, Pineda-Roman M, Hollmig K, Alsayed Y, Hoering A, Szymonifka J, Anaissie E, Petty N, Kumar NS, Srivastava G, Jenkins B, Crowley J, Zeldis JB. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood, 2008 Oct 15;112(8);3122-5. PMID: 18669874
  8. Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K, Alsayed Y, Waheed S, Petty N, Epstein J, Shaughnessy JD Jr, Tricot G, Zangari M, Zeldis J, Barer S, Crowley J. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood, 2008 Oct 15;112(8);3115-21. PMID: 18492953
  9. Barlogie B, Shaughnessy JD Jr, Crowley J. Retraction: Barlogie et al. Duration of survival in patients with myeloma treated with thalidomide. N Engl J Med 2008;359:210-2. N Engl J Med, 2008 Sep 25;359(13);1410. PMID: 18815407
  10. van Rhee F, Dhodapkar M, Shaughnessy JD Jr, Anaissie E, Siegel D, Hoering A, Zeldis J, Jenkins B, Singhal S, Mehta J, Crowley J, Jagannath S, Barlogie B. First thalidomide clinical trial in multiple myeloma: a decade.Blood, 2008 Aug 15;112(4);1035-8. PMID: 18502827
  11. Burington B, Barlogie B, Zhan F, Crowley J, Shaughnessy JD Jr. Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma. Clin Cancer Res, 2008 Aug 1;14(15);4821-9. PMID: 18676754
  12. Barlogie B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Crowley J. Making progress in treating multiple myeloma with total therapies: issue of complete remission and more. Leukemia, 2008 Aug;22(8);1633-6.PMID: 18305551
  13. Barlogie B, Anaissie E, Haessler J, van Rhee F, Pineda-Roman M, Hollmig K, Alsayed Y, Epstein J, Shaughnessy JD Jr, Crowley J. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer, 2008 Jul 15;113(2);355-9. PMID: 18470907
  14. Qiang YW, Shaughnessy JD Jr, Yaccoby S. Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood, 2008 Jul 15;112(2);374-82. PMID: 18344425
  15. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, Powell J, Dave S, Yu X, Zhao H, Zeng Y, Chen B, Epstein J, Staudt LM. IRF4 addiction in multiple myeloma. Nature, 2008 Jul 10;454(7201);226-31. PMID: 18568025
  16. Barlogie B, Shaughnessy JD Jr, Crowley J. Duration of survival in patients with myeloma treated with thalidomide. N Engl J Med, 2008 Jul 10;359(2);210-2. PMID: 18614793
  17. Lynch HT, Ferrara K, Barlogie B, Coleman EA, Lynch JF, Weisenburger D, Sanger W, Watson P, Nipper H, Witt V, Thomé S. Familial myeloma. N Engl J Med, 2008 Jul 10;359(2);152-7. PMID: 18614782
  18. Shaughnessy JD. Cancer: An unexpected addiction. Nature, 2008 Jul 10;454(7201);172-3. PMID: 18615074
  19. Li X, Pennisi A, Yaccoby S. Role of decorin in the antimyeloma effects of osteoblasts. Blood, 2008 Jul 1;112(1);159-68. PMID: 18436739
  20. Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J, Barlogie B, Shaughnessy JD Jr. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood, 2008 Jul 1;112(1);196-207.PMID: 18305214
  21. Gabrea A, Martelli ML, Qi Y, Roschke A, Barlogie B, Shaughnessy JD Jr, Sawyer JR, Kuehl WM. Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors. Genes Chromosomes Cancer, 2008 Jul;47(7);573-90. PMID: 18381641
  22. Pineda-Roman M, Zangari M, van Rhee F, Anaissie E, Szymonifka J, Hoering A, Petty N, Crowley J, Shaughnessy J, Epstein J, Barlogie B. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia, 2008 Jul;22(7);1419-27. PMID: 18432260
  23. Barlogie B, Haessler J, Pineda-Roman M, Anaissie E, van Rhee F, Kiwan E, Steward D, Gurley J, Jenkins B, Crowley J. Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs. Cancer, 2008 Jun 15;112(12);2720-5. PMID: 18433012
  24. Miceli MH, Grazziutti ML, Woods G, Zhao W, Kocoglu MH, Barlogie B, Anaissie E. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis, 2008 May 1;46(9);1412-22. PMID: 18419445
  25. Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y, Rice AG, van Abbema A, Wong M, Liu G, Zhan F, Dillon M, Chen S, Rhodes S, Fuh F, Tsurushita N, Kumar S, Vexler V, Shaughnessy JD Jr, Barlogie B, van Rhee F, Hussein M, Afar DE, Williams MB. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res, 2008 May 1;14(9);2775-84. PMID: 18451245
  26. Coleman EA, Coon SK, Kennedy RL, Lockhart KD, Stewart CB, Anaissie EJ, Barlogie B. Effects of exercise in combination with epoetin alfa during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for multiple myeloma. Oncol Nurs Forum, 2008 May;35(3);E53-61. PMID: 18467280
  27. Zangari M, van Rhee F, Anaissie E, Pineda-Roman M, Haessler J, Crowley J, Barlogie B. Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. Br J Haematol, 2008 May;141(4);433-44. PMID: 18371114
  28. Pineda-Roman M, Barlogie B, Anaissie E, Zangari M, Bolejack V, van Rhee F, Tricot G, Crowley J. High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients. Cancer, 2008 Apr 15;112(8);1754-64. PMID: 18300230
  29. Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD Jr. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone, 2008 Apr;42(4);669-80.PMID: 18294945
  30. Arzoumanian V, Hoering A, Sawyer J, van Rhee F, Bailey C, Gurley J, Shaughnessy JD Jr, Anaissie E, Crowley J, Barlogie B. Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia, 2008 Apr;22(4);850-5. PMID: 18200039
  31. Matsui S, Yamanaka T, Barlogie B, Shaughnessy JD Jr, Crowley J. Clustering of significant genes in prognostic studies with microarrays: application to a clinical study for multiple myeloma. Stat Med, 2008 Mar 30;27(7);1106-20. PMID: 17680552
  32. Pineda-Roman M, Zangari M, Haessler J, Anaissie E, Tricot G, van Rhee F, Crowley J, Shaughnessy JD Jr, Barlogie B. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol, 2008 Mar;140(6);625-34. PMID: 18302711
  33. Tian E, Landowski TH, Stephens OW, Yaccoby S, Barlogie B, Shaughnessy JD Jr. Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma. Mol Cancer Ther, 2008 Mar;7(3);500-9. PMID: 18319333
  34. Matsui S, Zeng S, Yamanaka T, Shaughnessy J. Sample size calculations based on ranking and selection in microarray experiments. Biometrics, 2008 Mar;64(1);217-26. PMID: 17680829
  35. Shi J, Tricot GJ, Garg TK, Malaviarachchi PA, Szmania SM, Kellum RE, Storrie B, Mulder A, Shaughnessy JD Jr, Barlogie B, van Rhee F. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood, 2008 Feb 1;111(3);1309-17. PMID: 17947507
  36. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA, . Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008 Feb;22(2);414-23. PMID: 18094721
  37. Yaccoby S, Pennisi A, Li X, Dillon SR, Zhan F, Barlogie B, Shaughnessy JD Jr. Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia, 2008 Feb;22(2);406-13. PMID: 18046446
  38. Zhan F, Barlogie B, Mulligan G, Shaughnessy JD Jr, Bryant B. High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood, 2008 Jan 15;111(2);968-9. PMID: 18182586
  39. Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, Barlogie B, Waage A, Aarset H, Dai HY, Shaughnessy JD Jr, Sundan A, Børset M. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Blood, 2008 Jan 15;111(2);806-15. PMID: 17934070
  40. Barlogie B, Tricot G, Haessler J, van Rhee F, Cottler-Fox M, Anaissie E, Waldron J, Pineda-Roman M, Thertulien R, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Crowley J, Sawyer J. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. Blood, 2008 Jan 1;111(1);94-100. PMID: 17895401
  41. Gokden N, Barlogie B, Liapis H. Morphologic heterogeneity of renal light-chain deposition disease.Ultrastruct Pathol, 2008 Jan-Feb;32(1);17-24. PMID: 18300034
  42. Van Ness B, Ramos C, Haznadar M, Hoering A, Haessler J, Crowley J, Jacobus S, Oken M, Rajkumar V, Greipp P, Barlogie B, Durie B, Katz M, Atluri G, Fang G, Gupta R, Steinbach M, Kumar V, Mushlin R, Johnson D, Morgan G.Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival. BMC Med, 2008;626. PMID: 18778477

2009

  1. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia, 2009 Dec;23(12);2210-2221. PMID: 19798094
  2. Driscoll JJ, Pelluru D, Lefkimmiatis K, Fulciniti M, Prabhala RH, Greipp PR, Barlogie B, Tai YT, Anderson KC, Shaughnessy JD Jr, Annunziata CM, Munshi NC. The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood, 2009 Nov 30; PMID: 19965618
  3. Qiang YW, Chen Y, Brown N, Hu B, Epstein J, Barlogie B, Shaughnessy Jr JD. Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma. Br J Haematol, 2009 Nov 24; PMID: 19961481
  4. Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, Benner A, Hundemer M, Rème T, Shaughnessy JD Jr, Barlogie B, Bertsch U, Hillengass J, Ho AD, Pantesco V, Jauch A, De Vos J, Rossi JF, Möhler T, Klein B, Hose D. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene, 2009 Nov 5;28(44);3866-79. PMID: 19718049
  5. Li X, Ling W, Pennisi A, Khan S, Yaccoby S. Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability. Cancer Lett, 2009 Nov 1;284(2);175-81. PMID: 19446953
  6. Sawyer JR, Tian E, Thomas E, Koller M, Stangeby C, Sammartino G, Goosen L, Swanson C, Binz RL, Barlogie B, Shaughnessy J. Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12 approximately 23 amplicon. Br J Haematol, 2009 Nov;147(4);484-94. PMID: 19744130
  7. Sanderson RD, Epstein J. Myeloma bone disease. J Bone Miner Res, 2009 Nov;24(11);1783-8. PMID: 19839769
  8. Zhou Y, Barlogie B, Shaughnessy JD Jr. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia, 2009 Nov;23(11);1941-56. PMID: 19657360
  9. Shaughnessy JD, Zhou Y, Haessler J, van Rhee F, Anaissie E, Nair B, Waheed S, Alsayed Y, Epstein J, Crowley J, Barlogie B. TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3. Br J Haematol, 2009 Nov;147(3);347-51. PMID: 19702643
  10. Coleman EA, Lynch H, Enderlin C, Stewart B, Thomé SD, Kennedy R, Richardson-Nelson T, Barlogie B. Initial report of a family registry of multiple myeloma. Cancer Nurs, 2009 Nov-Dec;32(6);456-64. PMID: 19816167
  11. Chen L, Wang S, Zhou Y, Wu X, Entin I, Epstein J, Yaccoby S, Xiong W, Barlogie B, Shaughnessy JD Jr, Zhan F.Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. Blood, 2009 Oct 16; PMID: 19837979
  12. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis, 2009 Oct 15;49(8);1211-25. PMID: 19769539
  13. Durie BG, Van Ness B, Ramos C, Stephens O, Haznadar M, Hoering A, Haessler J, Katz MS, Mundy GR, Kyle RA, Morgan GJ, Crowley J, Barlogie B, Shaughnessy J Jr. Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma. Leukemia, 2009 Oct;23(10);1913-9. PMID: 19657367
  14. Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Blade J, Lonial S, Dimopoulos MA, Einsele H, Barlogie B, Anderson KC, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV, Durie BG, . International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia, 2009 Oct;23(10);1904-12. PMID: 19554029
  15. Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, Alpe T, Angtuaco E, Walker R, Epstein J, Crowley J, Barlogie B. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood, 2009 Sep 3;114(10);2068-76.PMID: 19443657
  16. Anguiano A, Tuchman SA, Acharya C, Salter K, Gasparetto C, Zhan F, Dhodapkar M, Nevins J, Barlogie B, Shaughnessy JD Jr, Potti A. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J Clin Oncol, 2009 Sep 1;27(25);4197-203. PMID: 19636021
  17. van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R, Balasa B, Ganguly B, Chao D, Rice AG, Zhan F, Shaughnessy JD Jr, Barlogie B, Yaccoby S, Afar DE.Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther, 2009 Sep;8(9);2616-24. PMID: 19723891
  18. Pennisi A, Ling W, Li X, Khan S, Shaughnessy JD Jr, Barlogie B, Yaccoby S. The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood, 2009 Aug 27;114(9);1803-12. PMID: 19597185
  19. Hoering A, Crowley J, Shaughnessy JD Jr, Hollmig K, Alsayed Y, Szymonifka J, Waheed S, Nair B, van Rhee F, Anaissie E, Barlogie B. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. Blood, 2009 Aug 13;114(7);1299-305. PMID: 19515721
  20. Hussein MA, Bolejack V, Zonder JA, Durie BG, Jakubowiak AJ, Crowley JJ, Barlogie B. Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). J Clin Oncol, 2009 Jul 20;27(21);3510-7. PMID: 19546405
  21. Wang S, Tricot G, Shi L, Xiong W, Zeng Z, Xu H, Zangari M, Barlogie B, Shaughnessy JD Jr, Zhan F. RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma. Blood, 2009 Jul 16;114(3);600-7. PMID: 19458357
  22. Tricot G, Kern SE, Barlogie B. Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst, 2009 Jul 1;101(13);964-6; author reply 966-7. PMID: 19535776
  23. Nucci M, Anaissie E. Infections in patients with multiple myeloma. Semin Hematol, 2009 Jul;46(3);277-88.PMID: 19549580
  24. Nair B, Shaughnessy JD Jr, Zhou Y, Astrid-Cartron M, Qu P, van Rhee F, Anaissie E, Alsayed Y, Waheed S, Hollmig K, Szymonifka J, Petty N, Hoering A, Barlogie B. Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. Blood, 2009 Jun 25;113(26);6572-5. PMID: 19389881
  25. Zhou Y, Nair B, Shaughnessy JD Jr, Cartron MA, Haessler J, Anaissie E, van Rhee F, Crowley J, Barlogie B.Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile. Br J Haematol, 2009 Jun;145(5);637-41. PMID: 19344415
  26. Pennisi A, Li X, Ling W, Khan S, Gaddy D, Suva LJ, Barlogie B, Shaughnessy JD, Aziz N, Yaccoby S. Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease. Br J Haematol, 2009 Jun;145(6);775-87. PMID: 19388929
  27. Sprynski AC, Hose D, Caillot L, Réme T, Shaughnessy JD Jr, Barlogie B, Seckinger A, Moreaux J, Hundemer M, Jourdan M, Meissner T, Jauch A, Mahtouk K, Kassambara A, Bertsch U, Rossi JF, Goldschmidt H, Klein B. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood, 2009 May 7;113(19);4614-26. PMID: 19228610
  28. Brenne AT, Fagerli UM, Shaughnessy JD Jr, VÃ¥tsveen TK, Rø TB, Hella H, Zhan F, Barlogie B, Sundan A, Børset M, Waage A. High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis. Eur J Haematol, 2009 May;82(5);354-63. PMID: 19191868
  29. Hose D, Rème T, Meissner T, Moreaux J, Seckinger A, Lewis J, Benes V, Benner A, Hundemer M, Hielscher T, Shaughnessy JD Jr, Barlogie B, Neben K, Krämer A, Hillengass J, Bertsch U, Jauch A, De Vos J, Rossi JF, Möhler T, Blake J, Zimmermann J, Klein B, Goldschmidt H. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood, 2009 Apr 30;113(18);4331-40. PMID: 19171872
  30. Qiang YW, Hu B, Chen Y, Zhong Y, Shi B, Barlogie B, Shaughnessy JD Jr. Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood, 2009 Apr 30;113(18);4319-30. PMID: 19196662
  31. Nair B, Waheed S, Szymonifka J, Shaughnessy JD Jr, Crowley J, Barlogie B. Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols. Br J Haematol, 2009 Apr;145(1);134-7. PMID: 19120351
  32. Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD Jr, Evans HR, Snowden JA, Stover DR, Vanderkerken K, Croucher PI. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res, 2009 Mar;24(3);425-36. PMID: 19016584
  33. Sherman AC, Plante TG, Simonton S, Latif U, Anaissie EJ. Prospective study of religious coping among patients undergoing autologous stem cell transplantation. J Behav Med, 2009 Feb;32(1);118-28. PMID: 18855130
  34. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG, . International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia, 2009 Feb;23(2);215-24. PMID: 19020545
  35. Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, Rosol TJ, Shaughnessy JD Jr. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood, 2009 Jan 15;113(3);517-25. PMID: 18687985
  36. Sherman AC, Simonton S, Latif U, Plante TG, Anaissie EJ. Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation. Biol Blood Marrow Transplant, 2009 Jan;15(1);12-20. PMID: 19135938
  37. Pennisi A, Li X, Ling W, Khan S, Zangari M, Yaccoby S. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol, 2009 Jan;84(1);6-14. PMID: 18980173
  38. Zhou Y, Nair B, Shaughnessy JD Jr, Cartron MA, Haessler J, Anaissie E, van Rhee F, Crowley J, Barlogie B.Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile. Br J Haematol, 2009 Jun;145(5);637-41. PMID: 19344415
  39. Nair B, Shaughnessy JD Jr, Zhou Y, Astrid-Cartron M, Qu P, van Rhee F, Anaissie E, Alsayed Y, Waheed S, Hollmig K, Szymonifka J, Petty N, Hoering A, Barlogie B. Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. Blood, 2009 Jun 25;113(26);6572-5. PMID: 19389881
  40. Zhou Y, Barlogie B, Shaughnessy JD Jr. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia, 2009 Nov;23(11);1941-56. PMID: 19657360
  41. Nair B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Szymonifka J, Hoering A, Alsayed Y, Waheed S, Crowley J, Barlogie B. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with bortezomib, lenalidomide and dexamethasone (VRD) maintenance. Blood, 2010 Feb 2; PMID: 20124509
  42. Yaccoby S. Advances in the understanding of myeloma bone disease and tumour growth. Br J Haematol, 2010 Mar 11; PMID: 20230410
  43. Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams DR, Cartron MA, van Rhee F, Nair B, Waheed S, Pineda-Roman M, Alsayed Y, Anaissie E, Shaughnessy JD Jr. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci U S A, 2010 Apr 12; PMID: 2038581